First human test of new Huntington's disease drug begins
NCT ID NCT07246941
Summary
This is the first study in humans testing RG6496, a new drug for Huntington's disease. Researchers will give single, increasing doses to 40 people who carry the Huntington's disease gene to check if it's safe and well-tolerated. The study will also measure if the drug reduces the harmful protein that causes the disease in spinal fluid.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUNTINGTON'S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital Britanico de Buenos Aires
RECRUITINGCiudad Autonoma Bs As, C1280AEB, Argentina
-
New Zealand Brain Research Institute
RECRUITINGChristchurch, 8011, New Zealand
-
Westmead Hospital
RECRUITINGWestmead, New South Wales, 2145, Australia
Conditions
Explore the condition pages connected to this study.